Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Vitamins and plant ingredients

Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach

European Journal of Clinical Nutrition volume 69, pages 697–702 (2015)Cite this article

Subjects

Abstract

Background/Objectives:

The superiority of cholecalciferol (D3) over ergocalciferol (D2) in sustaining serum 25-hydroxy vitamin D (25OHD) levels is controversial. To compare D2 with D3 we performed a single-blind, placebo-controlled randomized trial spanning 11 weeks.

Subjects/Methods:

Healthy volunteers (n=33, aged 33.4±6 years) were divided into three groups (n=11, each): D2, D3 and placebo. Treatment started with a loading dose (100 000 IU) followed by 4800 IU/day (d) between d7 and d20 and follow-up until d77. Serum samples were obtained at baseline and at days 3, 7, 14, 21, 35, 49, 63 and 77.

Results:

Baseline 25OHD values in the D2 group were lower than those in the D3 and placebo groups (P<0.01). Placebo 25OHD levels never changed. As after the loading dose both D2 and D3 groups had reached similar 25OHD levels, we tested equivalence of the area under the concentration × time curve (AUC) between d7 and d77. The AUC was 28.6% higher for D3 compared with D2, and both were higher with respect to placebo. At d77, D2 25OHD levels were higher than those at baseline, but similar to placebo; both were lower than D3 (P<0.04). According to raw data, the elimination half-life of 25OHD was 84 and 111 days under D2 and D3 supplementation, respectively; after subtracting the placebo values, the corresponding figures were 33 and 82 days.

Conclusions:

D2 and D3 were equally effective in elevating 25OHD levels after a loading dose. In the long term, D3 seems more appropriate for sustaining 25OHD, which could be relevant for classic and non-classic effects of vitamin D.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Lips P . Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol 2010; 121: 297–300.

    Article  CAS  Google Scholar 

  2. Mithal A, Wahl DA, Bonjour JP, Burckardt P, Dawson-Hughes B, Eisman JA et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009; 20: 1807–1820.

    Article  CAS  Google Scholar 

  3. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B . Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18–28.

    Article  CAS  Google Scholar 

  4. Bikle D . Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009; 94: 26–34.

    Article  CAS  Google Scholar 

  5. Trivedi DP, Doll R, Khaw KT . Effect of four monthly oral vitamin D3 (Cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. Br Med J 2003; 326: 469.

    Article  CAS  Google Scholar 

  6. Mastaglia SR, Mautalen CA, Parisi MP, Oliveri B . 10.000 UI of oral vitamin D2 per day are required to rapidly reach adequate 25OHD levels in osteoporotic women. Eur J Clin Nutr 2006; 60: 1–7.

    Article  Google Scholar 

  7. Pepper KJ, Judd SE, Nanes M, Tangpricha V . Evaluation of vitamin D repletion regimens to correct vitamin D status in adults. Endocr Pract 2009; 15: 95–103.

    Article  Google Scholar 

  8. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willet WC . Benefit - risk assessment of vitamin D supplementation. Osteoporos Int 2010; 7: 1121–1132.

    Article  Google Scholar 

  9. Bikle D, Adams J, Christakos S . Vitamin D: production, metabolism, mechanism of action, and clinical requirements. In: Clifford Rosen (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th edn. American Society for Bone and Mineral Research: Washington, DC, USA, pp 141–149, 2008.

    Chapter  Google Scholar 

  10. Tjellesen L, Hummer L, Christiansen C, Rodbro P . Serum concentrations of vitamin D metabolites during treatment with vitamin D2 and D3 in normal premenopausal women. Bone Miner 1986; 1: 407–413.

    CAS  PubMed  Google Scholar 

  11. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R . Evidence that vitamin D3 increases 25-hydroxyvitamin D more efficiently than vitamin D2. Am J Clin Nutr 1998; 68: 854–858.

    Article  CAS  Google Scholar 

  12. Armas LA, Hollis BW, Heaney RP . Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 5387–5391.

    Article  CAS  Google Scholar 

  13. Rapuri PB, Gallagher JC, Haynatzki G . Effect of vitamin D2 and D3 supplement use on serum 25(OH)D concentration in elderly women in summer and winter. Calcif Tissue Int 2004; 74: 150–156.

    Article  CAS  Google Scholar 

  14. Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D́Erasmo E et al. Short and long term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab 2008; 93: 3015–3020.

    Article  CAS  Google Scholar 

  15. Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D et al. Vitamin D2 is as effective as vitamin D3 in mantaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677–681.

    Article  CAS  Google Scholar 

  16. Leventis P, Kiely PD . The tolerability and biochemical effects of high dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Scand J Rheumatol 2009; 38: 149–153.

    Article  CAS  Google Scholar 

  17. Glendenning P, Chew GT, Seymour HM, Guillet MJ, Goldsain PR, Inderjeeth CA et al. Serum 25 hydroxyvitamin D levels in vitamin D- insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. Bone 2009; 45: 870–875.

    Article  CAS  Google Scholar 

  18. Biancuzzo RM, Young A, Bibuld D, Cai MH, Winter MR, Klein EK et al. Fortification of orange juice with vitamin D2 or vitamin D3 is as effective as an oral supplement in maintaining vitamin D status in adults. Am J Clin Nutr 2010; 91: 1621–1626.

    Article  CAS  Google Scholar 

  19. Heaney RP, Recker RR, Grote J, Horst RL, Armas LAG . Vitamin D3 is more potent than vitamin D2 in humans. J Clin Endocrinol Metab 2011; 96: E447–E442.

    Article  CAS  Google Scholar 

  20. Binkley N, Gemar D, Engelke J, Gangnon R, Ramamurthy R, Krueger D et al. Evaluation of ergocalciferol or cholecalciferol dosing, 1600UI daily or 50000IU monthly in older adults. J Clin Endocrinol Metab 2011; 96: 981–988.

    Article  CAS  Google Scholar 

  21. Seijo M, Mastaglia SR, Brito G, Somoza J, Oliveri B . ¿Es equivalente la suplementación diaria con vitamina D2 o vitamina D3 en adultos mayores? Medicina 2012; 72: 195–200.

    CAS  PubMed  Google Scholar 

  22. Vieth R, Chan PCR, Mac Fairline GD . Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect levels. Am J Clin Nutr 2001; 73: 288–294.

    Article  CAS  Google Scholar 

  23. Brito GM, Mastaglia SR, Goedelman C, Seijo M, Somoza J, Oliveri B . Estudio exploratorio de la ingesta y prevalencia de vitamina D en mujeres mayores de 65 años que viven en hogar familiar o en residencias para autoválidos de la Ciudad de Buenos Aires. Nutrición Hospitalaria 2013; 28: 816–822.

    CAS  PubMed  Google Scholar 

  24. IOM Dietary Reference Intake for calcium and vitamin D. The National Academies Press: Washington DC, 2011.

  25. Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, Vanderschueren D et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab 2013; 98: E1283–E1304.

    Article  CAS  Google Scholar 

  26. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911–1930.

    Article  CAS  Google Scholar 

  27. Hsuan FC . Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies. Biometrics1993 49: 703–713.

  28. Chow SC, Liu JP . Design and analysis of bioavailability and bioequivalence studies. 2nd edn. Marcel Dekker: New York, NY, USA, 2000.

    Google Scholar 

  29. Anderson S, Hauck WW . A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Comm Statist Theory Methods 1983; 12: 2663–2692.

    Article  Google Scholar 

  30. Schuirmann DJ . A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657–680.

    Article  CAS  Google Scholar 

  31. US Food and Drug Administration Guidance for Industry. Statistical approaches to establishing bioequivalence. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf. Last accessed on 15 October 2013.

  32. Wacker M, Holick FH . Vitamin D. Effects on skeletal and extraskeletal health and the need for supplementation. Nutrients 2013; 5: 111–148.

    Article  CAS  Google Scholar 

  33. Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr 2012; 95: 1357–1364.

    Article  CAS  Google Scholar 

  34. Ladizesky M, Oliveri B, Mautalen CA . Niveles séricos de 25-hidroxivitamina D en la población normal de Buenos Aires, su variación estacional. Medicina 1987; 47: 268–272.

    CAS  PubMed  Google Scholar 

  35. Ladizesky M, Lu Z, Oliveri MB, San Román N, Holick M, Mautalen CA . Solar ultraviolet - B radiation and photoproduction of vitamin D in Central and Southern areas of Argentina. J Bone Min Res 1995; 10: 545–549.

    Article  CAS  Google Scholar 

  36. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ . Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204–210.

    Article  CAS  Google Scholar 

  37. Hollis BW . Comparison of equilibrium and disequilibrium assay conditions for ergocalciferol, cholecalciferol and their major metabolites. J Steroid Biochem 1984; 12: 81–86.

    Article  Google Scholar 

  38. Nimitphong H, Saetung S, Chanprasertyotin S, Chailurkit LO, Ongphiphadhanakul B . Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D3 or D2 supplementation. Nutr J 2013; 12: 39.

    Article  CAS  Google Scholar 

  39. Nilsson SF, Ostberg L, Peterson PA . Binding of vitamin D to its human carrier plasma protein 1972. Biochem Byophys Res Commun 1972; 46: 1380–1387b.

    Article  CAS  Google Scholar 

  40. Schuster I . Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2011; 1814: 186–199.

    Article  CAS  Google Scholar 

  41. Spedding S, Vanlint S, Morris H, Seragg R . Does vitamin D sufficiency equate to a single serum 25-hydroxyvitamin D level or are different levels required for non-skeletal diseases? Nutrients 2013; 5: 5127–5139.

    Article  CAS  Google Scholar 

  42. Hollis BW, Wagner C . The role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocr Metab 2013; 98: 4619–4628.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

BO and SRM are members of the research career of CONICET (Argentina's National Research Council); JS is a member of support career of CONICET. We are indebted to the pharmaceutical companies Roemmers, Spedrog Caillon and Gador, which supplied the vials of Vitamin D2, Vitamin D3 and calcium, respectively. This research received financial support from grant PICT # 523 of Argentina's National Agency for the Promotion of Science and Technology (ANPCyT).

Author information

Authors and Affiliations

  1. Laboratorio de Enfermedades Metabólicas Óseas, INIGEM-CONICET-UBA, Hospital de Clínicas,, Buenos Aires, Argentina

    B Oliveri, S R Mastaglia, G M Brito, M Seijo & J Somoza

  2. Segunda Cátedra de Farmacología, Facultad de Medicina, Universidad de Buenos,, Buenos Aires, Argentina

    G A Keller, R A Diez & G Di Girolamo

Authors
  1. B Oliveri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S R Mastaglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G M Brito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Seijo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G A Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Somoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R A Diez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Di Girolamo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Oliveri.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Oliveri, B., Mastaglia, S., Brito, G. et al. Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. Eur J Clin Nutr 69, 697–702 (2015). https://doi.org/10.1038/ejcn.2015.16

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ejcn.2015.16

This article is cited by

Search

Advanced search

Quick links